Aminopropionitrile has a strong effect in the treatment of HCC and can be used as a potential therapeutic drug targeting LOXL3-related pathways, providing a new intervention direction for improving chemoresistance and inhibiting tumor progression in HCC. The gene discussed is LOXL3; the disease is hepatocellular carcinoma.